Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennifer Chien - EVP, Head of North America Yann Mazabraud - EVP, Head of International Hunter Smith - CFO Conference Call Participants Corinne Jenkins - Goldman Sachs Phil Nadeau - TD Cowen Derek Archila - Wells Fargo Dae Gon Ha - Stifel Jeff Hung - Morgan Stanley Whitney ...

® ® 2 | --- | --- | |-------|------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | David Meeker, MD | | | | | | | | | | | | | | | | | 4 | Rhythm® | • More than 100 international patients on reimbursed IMCIVREE therapy • 25.5% mean BMI reduction achieved at one-year setmelanotide therapy (n=12) in LTE trial, as presented at ObesityWeek® • RM-718: IND on track for submission by year-end 2023 Weight Reduction in Patients with Hypothalamic Obesity Treated With Setmelanotide for 12 Months 4-Yea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or ot ...

• IMCIVREE now commercially available in Canada, GCC states; German BBS launch underway • 12-month data planned for fall conference • Additional detail on development programs at 4Q R&D event 6 Investigational New Drug (IND) application on track to be filed by end of 2023 *Includes patent term adjustment and patent term extension. Heterozygous POMC/PCSK1 insufficiency *Estimated prevalence of U.S. patients based on company estimates; does not include ex-U.S. prevalence estimates. 53,000 patients in the U.S. ...

Start Time: 08:00 January 1, 0000 8:51 AM ET Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2023 Earnings Conference Call August 01, 2023, 08:00 AM ET Company Participants David Meeker - Chairman, President, and CEO Jennifer Chien - EVP, Head of North America Yann Mazabraud - EVP, Head of International Hunter Smith - CFO David Connolly - Executive Director, IR and Corporate Communications Conference Call Participants Divya Rao - TD Cowen Derek Archila - Wells Fargo Corinne Jenkins - Goldman Sachs Dae Gon Ha ...

® David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of International Hunter Smith, Chief Financial Officer ® May 2, 2023 On Today's Call Important Notice | --- | --- | |-------|------------------| | | | | | | | | | | | | | | | | | | | | | | | David Meeker, MD | | | | | | | | 4 | ! Rhythm® | • Strong s ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants David Connolly - Executive Director of Investor Relations and Corporate Communications David Meeker - Chairman, President, and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Derek Archila - Well ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or o ...

Table of Contents ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-2159271 (State or Othe ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Derek Archila - Wells Fargo Se ...